Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine
Gastroenterology
Dr. Stephen B. Hanauer, MD
|
|
Give Review
Stephen Hanauer is an expert in the field of Gastroenterology. He attended University of Illinois College of Medicine. He received 9 awards: "President", "America's Top Doctors", "Chicago Magazine: Top Doctors", "CMS Meaningful Use Stage 1 Certification", "Fellow (AGAF)", "Women's Health", "Super Doctor", "Top MD" and "Fellow (FACG)". Doctor Stephen B. Hanauer, MD has written publications. He has 90 publications published with PubMed. The lastest publication is: 'The Crohn's Disease-Ulcerative Colitis Clinical Appraisal.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Hyperacute Methotrexate Pneumonitis in a Patient With Crohn's Disease.
- O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα...
- Surveillance of IBD Using High Definition Colonoscopes Does Not Miss Adenocarcinoma in Patients with Low-grade Dysplasia.
- The Crohn's Disease-Ulcerative Colitis Clinical Appraisal.
- Balancing the risks and benefits of biologic therapy in inflammatory bowel Diseases.
- Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.
- The holy grail, or only half way there?
- Incidence and Predictors of Clinical Response, Re-induction Dose, and Maintenance Dose Escalation with Certolizumab Pegol in Crohn's Disease.
- Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.
- Effects of Vedolizumab Induction Therapy for Patients With Crohn's Disease in Whom Tumor Necrosis Factor Antagonist Treatment Had Failed.
- AST-120 (Spherical Carbon Adsorbent) in the Treatment of Perianal Fistulae in Mild-to-Moderate Crohn's Disease: FHAST-1, a Phase 3, Multicenter, Placebo-controlled Study.
- American Gastroenterological Association Institute Technical Review on the Use of Thiopurines, Methotrexate, and Anti-TNF-α Biologic Drugs for the Induction and Mainte...
- Randomised clinical trial: individualised vs. weight-based dosing of azathioprine in Crohn's Disease.
- Still in Pursuit.
- Mucosal healing is associated with improved long-term outcome of maintenance therapy with natalizumab in Crohn's Disease.
- Treat to Target: A Proposed New Paradigm for the Management of Crohn's Disease.
- A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's Disease.
- Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's Disease.
- Vedolizumab as induction and maintenance therapy for Crohn's Disease.
- Inflammation is an independent risk factor for colonic neoplasia in patients with Ulcerative colitis: a case-control study.
- Gene signature distinguishes patients with chronic Ulcerative colitis harboring remote neoplastic lesions.
- Quality Indicators for Inflammatory Bowel Disease: Development of Process and Outcome Measures.
- Ciprofloxacin for the Prevention of Postoperative Recurrence in Patients with Crohn's Disease: A Randomized, Double-blind, Placebo-controlled Pilot Study.
- Natalizumab in Crohn's Disease: Results From a US Tertiary Inflammatory Bowel Disease Center.
- Safety and Tolerability of Human Placenta-Derived Cells (PDA001) in Treatment-Resistant Crohn's Disease: A Phase 1 Study.
- Reassessing the Risks and Benefits of Thiopurines in Crohn's Disease.
- Long-term treatment of patients with a history of ulcerative colitis who develop gastritis and pan-Enteritis after colectomy.
- In memoriam.
- Joseph Barnett Kirsner, MD, PhD.
- In Memoriam: Joseph Barnett Kirsner, MD, PhD.
- Association Between Higher Predicted Serum Vitamin D Levels and Reduced Incidence of Inflammatory Bowel Diseases.
- Disease Modification in Inflammatory Bowel Disease.
- Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel Disease.
- Two Brothers with Skewed Thiopurine Metabolism in Ulcerative Colitis Treated Successfully with Allopurinol and Mercaptopurine Dose Reduction.
- Efficacy of Topical 5-Aminosalicylates in Preventing Relapse of Quiescent Ulcerative Colitis: A Meta-analysis.
- Developing an instrument to assess the endoscopic severity of Ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS).
- Calcineurin inhibition in severe Ulcerative colitis: Lost in translation?
- Early Mucosal Healing With Infliximab is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis.
- miR-143 and miR-145 are downregulated in Ulcerative colitis: Putative regulators of inflammation and protooncogenes.
- Long-term infliximab maintenance therapy for Ulcerative colitis: The ACT-1 and -2 extension studies.
- Efficacy of biological therapies in inflammatory bowel disease: Systematic review and meta-analysis.
- Assessing Response and Loss of Response to Biological Therapies in IBD.
- Shared experiences and best practices in the management of rheumatoid arthritis and Crohn's Disease.
- Predictors of adalimumab dose escalation in patients with crohn's Disease at a tertiary referral center.
- Practical application of anti-TNF therapy for luminal Crohn's Disease.
- The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start...
- Clinical scenarios in IBD: optimizing the use of conventional and biologic agents.
- Outcome after surveillance of low-grade and indefinite dysplasia in patients with Ulcerative colitis.
- African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity.
- Prospective randomized open-label multicenter phase I/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory Ulcerative colitis.
- Optimizing conventional therapies for inflammatory bowel Disease.
- Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active Ulcerative colitis.
- Positioning biologic agents in the treatment of Crohn's Disease.
- Colectomy rate comparison after treatment of Ulcerative colitis with placebo or infliximab.
- Open-label study of adalimumab in patients with Ulcerative colitis including those with prior loss of response or intolerance to infliximab.
- Exploring the controversial themes of IBD.
- Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's Disease: a meta-analysis.
- Emerging issues in Ulcerative colitis and Ulcerative proctitis: individualizing treatment to maximize outcomes.
- Management of Crohn's Disease in adults.
- Defining the optimal response criteria for the Crohn's Disease activity index for induction studies in patients with mildly to moderately active Crohn's Disease.
- Early aggressive therapy for Crohn's Disease.
- Biologic therapy for inflammatory bowel Disease comes of age.
- The role of loperamide in gastroIntestinal disorders.
- Risks and benefits of the use of concomitant immunosuppressives and biologics in inflammatory bowel Disease.
- Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's Disease.
- Effect of long-term low-dose prednisone on height velocity and Disease activity in pediatric and adolescent patients with Crohn Disease.
- American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel Disease, June 21-23, 2006.
- Adalimumab induction therapy for Crohn Disease previously treated with infliximab: a randomized trial.
- Acute and chronic megacolon.
- Are dysplasia and Colorectal cancer endoscopically visible in patients with ulcerative colitis?
- Smoking and inflammatory bowel Disease: trends in familial and sporadic cohorts.
- Feasibility and utility of an electronic diary to assess self-report symptoms in patients with inflammatory bowel Disease.
- The effects of infliximab therapy on health-related quality of life in Ulcerative colitis patients.
- Effect of allopurinol on clinical outcomes in inflammatory bowel Disease nonresponders to azathioprine or 6-mercaptopurine.
- A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with Ulcerative colitis.
- Refining the role of TNF antagonists for Crohn's Disease. Introduction.
- Treatment of diarrhea in patients with inflammatory bowel Disease: concepts and cautions.
- The benefits of loperamide in the treatment of patients with IBS or IBD. Introduction.
- A randomized, placebo-controlled, phase II study of tetomilast in active Ulcerative colitis.
- Adalimumab for maintenance of clinical response and remission in patients with Crohn's Disease: the CHARM trial.
- Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's Disease not in remission while receiving infliximab.
- Clinical perspectives in Crohn's Disease. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down".
- General principles and pharmacology of biologics in inflammatory bowel Disease.
- Aminosalicylate therapy in the prevention of dysplasia and Colorectal cancer in ulcerative colitis.
- Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease.
- Inflammatory bowel Disease characteristics among African Americans, Hispanics, and non-Hispanic Whites: characterization of a large North American cohort.
- Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's Disease.
- Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's Disease.
- Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive Ulcerative colitis locus.
Schools
University of Illinois At Chicago College of Medicine
Procedures Preformed
- Colonoscopy, Proctosigmoidoscopy, and Sigmoidoscopy
- Endoscopy (Esophagus, Stomach, Small Intestine)
Conditions Treated
- Abdominal Pain
- Anemia
- Barrett's Esophagus
- Benign Neoplasm of the Digestive System
- View All
Doctors Specialties
- Gastroenterology
Accepted Insurances
Awards
- President
- America's Top Doctors
- Chicago Magazine: Top Doctors
- CMS Meaningful Use Stage 1 Certification
- Fellow (AGAF)
- Women's Health
- Super Doctor
- Top MD
- Fellow (FACG)
Education
-
University of Chicago -
University of Illinois College of Medicine
Hospital
-
University of Chicago Medical Center -
Northwestern Memorial Hospital
Drug Facts
| NPI NUMBER | 1992868418 | |
| NPPES Provider LastName | HANAUER | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 605276686 | |
| NPPES Provider State | IL | |
| Specialty Description | Gastroenterology | |
| Total Claim Count | 705.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1992868418 |
| Last Name Of The Provider | HANAUER |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Michael O. Blackstone, MD |
|
|
Dr. David T. Rubin, MD |
|
|
Dr. Laura Kulik, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Josh Levitsky, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ramon A. Garcia Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Neehar Dilip D. Parikh, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adam C. Stein, MD |
|
|
Dr. Jose A. Albisu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kevin B. Patel, MD |
|
|
Dr. Sheena K. Patel, MD |